The development of effective therapies for colorectal cancer depends on the ability of preclinical models to faithfully recapitulate the molecular and biological behavior of human tumors. This study reports the characterization of colorectal GEMMs and their derivative cell lines carrying wild-type or oncogenic Kras with concomitant Apc and p53 loss.
Mouse models of Kras mutant colorectal cancer: valuable GEMMs for drug testing?
DI NICOLANTONIO, Federica;BARDELLI, Alberto
2013-01-01
Abstract
The development of effective therapies for colorectal cancer depends on the ability of preclinical models to faithfully recapitulate the molecular and biological behavior of human tumors. This study reports the characterization of colorectal GEMMs and their derivative cell lines carrying wild-type or oncogenic Kras with concomitant Apc and p53 loss.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2013_DiNicolantonio_ClinCancerRes_PDF_Editoriale.pdf
Accesso riservato
Descrizione: Articolo principale (PDF Editoriale)
Tipo di file:
PDF EDITORIALE
Dimensione
412.87 kB
Formato
Adobe PDF
|
412.87 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
2013_DiNicolantonio_ClinCancerRes_postprint2_4aperto.pdf
Accesso aperto
Descrizione: Articolo principale
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
1.08 MB
Formato
Adobe PDF
|
1.08 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
